Culture

Boston, MA-- The investigational drug abaloparatide-SC (subcutaneous) may help increase bone mineral density in postmenopausal women and reduce their risk of fracture, new industry-sponsored research suggests. The results of the subgroup analysis within the ACTIVE clinical trial will be presented Friday, April 1, at ENDO 2016, the annual meeting of the Endocrine Society in Boston.

Steven E. Nissen, M.D., of the Cleveland Clinic, and colleagues identified patients with muscle-related adverse effects from statins and compared lipid-lowering efficacy for two nonstatin therapies, ezetimibe and evolocumab. The study was published online by JAMA, and is being released to coincide with its presentation at the American College of Cardiology's 65th Annual Scientific Session & Expo.

Sunday, April 3, 2016, Chicago: In the first major trial of its kind, Cleveland Clinic researchers used a blinded rechallenge with atorvastatin or placebo to objectively confirm the presence of muscle-related symptoms in patients with a history of intolerance to multiple statins and found that evolocumab (a PCSK9 inhibitor) was a more effective option to lower cholesterol than ezetimibe in these patients.

The double-blinded, placebo-controlled clinical trial was designed with two stages:

CHICAGO - Patients who arrive at the emergency department with low-risk chest pain and talk through treatment options with a physician show improved knowledge of their health status and follow-up options, compared with patients who received standard counseling from a physician, according to Mayo Clinic research presented at the American College of Cardiology's 65th Annual Scientific Session.

Findings from the early phase of a clinical trial led by Johns Hopkins investigators indicates that a new, minimally invasive weight loss treatment known as bariatric arterial embolization is safe and effective in sustaining weight loss in severely obese people.

VANCOUVER, British Columbia (April 3, 2016)--Women who underwent a nonsurgical, image-guided treatment, uterine fibroid embolization (UFE), for the treatment of uterine fibroids experienced improved sexual function and a higher overall quality of life. The research, part of a French multicenter study, presented at the Society of Interventional Radiology's Annual Scientific Meeting, also found the vast majority of women treated with UFE sustained improvement for more than a year.

Depression is a known risk factor for cardiovascular disease, but as a person's depression improves -- or grows worse -- their risk for heart disease has remained largely unknown.

But now, a new study by researchers at the Intermountain Medical Center Heart Institute in Salt Lake City found that effectively treating depression can reduce a patient's chance of having a stroke, heart failure, a heart attack or death.

In fact, effective treatment for depression can reduce a patient's heart risks to the same level as those who never had short-term depression, the study found.

Boston, MA-- A new low-dose vaginal estrogen capsule may help relieve symptoms of menopausal vulvar and vaginal atrophy, including dyspareunia (pain during sex), new industry-sponsored research reports. The study results will be presented in a late-breaking poster Saturday, April 2, at ENDO 2016, the annual meeting of the Endocrine Society, in Boston.

Boston, MA-- Combining a temporary one-year intestinal bypass device with the drug liraglutide helps patients lose weight and improve their diabetes control better than using either the device or the drug alone, new research from the United Kingdom reports. The one-year results of the two-year study will be presented in a poster Saturday, April 2, at ENDO 2016, the annual meeting of the Endocrine Society in Boston.

Boston, MA-- Most people lose, gain and maintain their weight inconsistently, and those who lose the most weight are most likely to keep it off and keep losing, new research reports. The study results will be presented Friday, April 1, at ENDO 2016, the annual meeting of the Endocrine Society, in Boston.

A new study from the Intermountain Medical Center Heart Institute in Salt Lake City and John Hopkins Hospital in Baltimore lends more evidence to the idea that it's better to be shaped like a pear -- with weight around the hips -- as opposed to an apple -- with weight around the abdomen.

Researchers from the two centers found that abdominal obesity -- or having an apple-shaped body -- is a strong predictor of serious heart disease in patients who have type 1 or type 2 diabetes, and haven't displayed any symptoms of heart disease.

(BOSTON) - Researchers from Massachusetts Eye and Ear and Schepens Eye Research Institute have shown an association between a defective myogenic response -- the regulatory increase or decrease in blood pressure to keep blood flow within the vessels of the retina constant -- and early, accelerated development of retinopathy in patients with type 1 diabetes.

Boston, MA-- Elderly adults are bigger around the middle when they turn up the heat inside their homes during the cold season and have smaller waistlines when their homes stay cool, new research finds. Investigators from Japan will present their study results Friday at the Endocrine Society's 98th annual meeting in Boston.

Boston, MA-- Lifestyle changes that include healthier diet and routine physical exercise help older overweight and obese adults with Type 2 diabetes improve glucose control, body composition, physical function and bone quality, according to preliminary findings of an ongoing clinical trial. The six-month results of the one-year study will be presented Friday, April 1, at ENDO 2016, the annual meeting of the Endocrine Society, in Boston.

Boston, MA-- Among military veterans identifying as transgender, 90 percent have at least one mental health diagnosis, such as posttraumatic stress disorder (PTSD) or depression, and nearly 50 percent had a hospitalization after a suicide attempt or suicidal thoughts. These study findings, from a single veterans' hospital, will be presented Friday at The Endocrine Society's 98th annual meeting in Boston.